Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

G-Protein Gated Ion Channels01:21

G-Protein Gated Ion Channels

GPCRs are primarily responsible for our sense of smell, taste, and vision.  The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory organs,...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Junctophilin-2-orchestrated calcium signalosome regulates brown adipocyte thermogenesis and energy metabolism.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Peripartum-Associated Heart Failure Develops Independently of RHOT Proteins.

International journal of molecular sciences·2026
Same author

Adipose Tissue Plasticity, Lipoprotein Metabolism, and Cardiovascular Risk: The Emerging Role of the GLP-1 Axis.

Circulation research·2026
Same author

Choice of cardioplegia influences metabolomics of human cardiac tissue.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Stabilizing and strengthening the US physician-scientist faculty workforce in academic medicine: a proposed institutional framework.

JCI insight·2026
Same author

Dyssynchronous heart failure: mitochondrial distribution and functions mirror regional workload and energy demand in a large-animal model of ventricular desynchronization.

European journal of heart failure·2026

Related Experiment Video

Updated: May 19, 2026

In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter
05:04

In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter

Published on: February 22, 2022

PGC-1 proteins and heart failure.

Christian Riehle1, E Dale Abel

  • 1Division of Endocrinology, Metabolism and Diabetes, Program in Molecular Medicine, University of Utah School of Medicine, Salt Lake City, UT 84112, USA.

Trends in Cardiovascular Medicine
|September 4, 2012
PubMed
Summary
This summary is machine-generated.

Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) and PGC-1β are key regulators of energy production in the heart. Their repression during heart failure impairs cardiac function, but maintaining their expression preserves heart muscle performance.

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

Related Experiment Videos

Last Updated: May 19, 2026

In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter
05:04

In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter

Published on: February 22, 2022

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

Area of Science:

  • Molecular biology
  • Cardiovascular research
  • Metabolic regulation

Background:

  • PGC-1α and PGC-1β are crucial transcriptional coactivators.
  • They regulate genes involved in oxidative phosphorylation and fatty acid oxidation.
  • Cardiac pressure overload and heart failure lead to decreased PGC-1α and PGC-1β expression.

Purpose of the Study:

  • To discuss the regulation of PGC-1 proteins.
  • Focus on conditions of pressure overload hypertrophy and heart failure.
  • Highlight the role of PGC-1 in maintaining cardiac function.

Main Methods:

  • Review of existing literature on PGC-1 regulation.
  • Analysis of gene expression changes in cardiac hypertrophy and failure models.
  • Discussion of functional consequences of PGC-1 modulation.

Main Results:

  • PGC-1α and PGC-1β expression is significantly reduced in pressure overload hypertrophy and heart failure.
  • Reduced PGC-1 expression correlates with impaired oxidative metabolism and contractile dysfunction.
  • Preservation of PGC-1α and PGC-1β levels can maintain cardiac contractile function despite increased workload.

Conclusions:

  • PGC-1α and PGC-1β are critical for cardiac adaptation to stress.
  • Dysregulation of these coactivators contributes to heart failure pathogenesis.
  • Therapeutic strategies targeting PGC-1 pathways may offer benefits for heart failure treatment.